Concepedia

Mauricio Burotto

MB

Statistics

Publications

66

Citations

6.7K

H-Index

30

Active since

2001

Affiliations

Institut Gustave Roussy(Current)

Dana-Farber Cancer Institute

Bristol-Myers Squibb (United States)

Memorial Sloan Kettering Cancer Center

Queen Mary University of London

Mauricio Burotto is an author at Institut Gustave Roussy specializing in medicine, oncology, and cancer immunotherapy.

ORCID

Publications per year

2001–2025

66

Publications

66

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

, , +9

Pseudoprogression and Immune-Related Response in Solid Tumors

Victoria L. Chiou, Mauricio Burotto · Journal of Clinical Oncology · 2015 · 909 citations

, , +17

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Laurence Albigès, Nizar M. Tannir, Mauricio Burotto et al. · ESMO Open · 2020 · 522 citations · Full text

, , +17

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles et al. · New England Journal of Medicine · 2023 · 462 citations · Full text

, , +17

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto et al. · The Lancet Oncology · 2022 · 307 citations · Full text

, , +10

1–5 of 66